Adjuvant treatment | Recommendation | ||||||||
---|---|---|---|---|---|---|---|---|---|
Modality | Expertise | Recorded | Recommended | Not Recommended | For discussion | ||||
N | (%) | N | (%) | N | (%) | N | (%) | ||
Chemotherapy | MDT | 975 | (92) | 342 | (35) | 393 | (40) | 240 | (25) |
ESMO | 1065 | (100) | 321 | (30) | 701 | (66) | 43 | (4) | |
NCCN | 1065 | (100) | 489 | (46) | 80 | (8) | 496 | (47) | |
Endocrine therapy | MDT | 1002 | (94) | 794 | (79) | 86 | (9) | 122 | (2) |
ESMO | 1065 | (100) | 927 | (87) | 138 | (13) | 0 | (0) | |
NCCN | 1065 | (100) | 874 | (82) | 143 | (13) | 48 | (5) | |
Trastuzumab | MDT | 456 | (43) | 86 | (19) | 363 | (80) | 7 | (2) |
ESMO | 1065 | (100) | 142 | (13) | 923 | (87) | 0 | (0) | |
NCCN | 1065 | (100) | 125 | (12) | 929 | (87) | 11 | (1) |